Delhi HC asks DGCI to decide representation over weight-loss drugs
A bench of Chief Justice D K Upadhyaya and Justice Tushar Rao Gedela asked the petitioner to give a representation to the DGCI, which was asked to decide the matter within three months.
New Delhi, Jul 2 (PTI) The Delhi High Court on Wednesday asked the Drug Controller General of India to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight loss treatment.
In an apparent reference to the recent death of popular TV actor Shefali Jariwala, the court said, 'See what happened two-three days back…' News reports suggest Jariwala was taking anti-ageing treatment for the last several years.
The petitioner claimed the licenses have been issued without conducting any specific trials and studies and without noting the serious adverse health effects of the drugs.
'These drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, with their primary therapeutic role being the regulation of glycemic levels. However, over the past few years, they have been repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials,' the plea said.
It said under the Drugs and Cosmetics Act, it is the DCGI which is the competent and statutory authority entrusted with taking appropriate measures to ensure safe use of drugs.
The petitioner said representations were made on April 18 to the Centre and DCGI on the issue.
The court, however, said the plea's concerns have to be first looked into and addressed by the DCGI as it allowed the petitioner to move the authority by way of an additional representation and bring relevant material and documents to its notice.
The additional representation was directed to be submitted to the DGCI within a fortnight.
'In case such an additional representation is preferred enclosing all the documents and material necessary for addressing the issue raised in the writ petition, the same shall be attended to and considered appropriately and as per law by the authority concerned,' the court said.
The order added, 'DCGI shall consult experts as also other stakeholders such as manufacturers of the drugs in question.' PTI SKV SKV AMK AMK
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
AIIMS moves Delhi HC against order allowing minor rape survivor to terminate pregnancy
All India Institute of Medical Sciences ( AIIMS ) on Thursday moved the Delhi High Court against an order allowing a 27-week minor rape survivor to terminate pregnancy. A high court single judge on June 30 ordered AIIMS to terminate the 16-year-old girl's pregnancy. AIIMS, before a bench of Chief Justice D K Upadhyaya and Justice Anish Dayal, argued that terminating her pregnancy would hamper her future reproductive health. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The bench asked the mother of the minor girl and chairperson or a member of the medical board to remain present at around 2.30 pm when hearing would continue. The court also remarked that "advising a rape victim to prolong her pregnancy will entail anxiety " which could have a grave impact on her mental health. Live Events Additional solicitor general Aishwarya Bhati, representing AIIMS, said the medical board opined that the girl's health needed to be protected. "As an officer of the court today I am urging your lordships to be 'parens patriae' of this young girl and protect her. She does not want the child, understandable. We, in AIIMS, will do everything best for the child," he submitted. On the court's query whether it would be safe to terminate the pregnancy after 34 weeks, Bhati replied in the affirmative. She, however, underlined the precarious situation right now and the girl's well-being, prompting AIIMS to move court. Bhati said the girl was 27-week pregnant and the termination of her pregnancy would jeopardise her reproductive life and future chances of conceiving. Referring to the relevant law, Bhati said pregnancy could be terminated after 24 weeks of gestation period only in two situations - if there is a grave risk to the woman's life or congenital anomalies in the fetus. AIIMS moved against a single judge's June 30 order allowing the minor sexual assault survivor to terminate her then 26-week pregnancy. It came on record that the medical board was not in favour of allowing the termination of pregnancy in view of the advanced gestational age requiring most likely a cesarean section procedure which could adversely affect the girl's future reproductive health. The medical board opined that the girl was otherwise physically fit. The girl and her mother, however, insisted on not continuing with the pregnancy. She moved the court after the doctors expressed their inability to proceed due to the statutory restrictions provided under the MTP Act, limiting such procedures to 20 weeks in ordinary cases and 24 weeks in certain categories such as rape survivors. According to the girl's lawyer, the minor was sexually assaulted by a man during Diwali in 2024 but she did not disclose the incident to anyone. She was again sexually assaulted in March by another person, resulting in her pregnancy, her lawyer said. She learnt about the pregnancy only when she went to a doctor with her sister and when her family members got to know, she confided in them about the sexual assault, leading to the filing of the FIR. At the time of the FIR in June, the gestational age exceeded the prescribed 24-week limit. The police arrested the accused of the March sexual assault incident whereas the man who assaulted her last year is yet to be nabbed, the court was informed. The single judge in its order recorded judgments, including that of the Supreme Court, in which pregnancy was allowed to be terminated in cases where gestational period exceeded 27 weeks and even of 33 weeks. The AIIMS doctors, as a result, were ordered to maintain a complete record of the procedure aside from preserving the fetus tissue, which could be required for DNA identification and investigation purposes. The court further directed the state authorities to bear all the expenses of the medical procedure, the girl's stay at the hospital and the expenditure of post-operative care.
Hindustan Times
3 hours ago
- Hindustan Times
Kiran Mazumdar-Shaw hits back at Karnataka CM Siddaramaiah for hinting COVID vaccines are behind heart attacks in Hassan
Biocon Executive Chairperson Kiran Mazumdar-Shaw has strongly criticized Karnataka Chief Minister Siddaramaiah for suggesting that COVID-19 vaccines may be linked to a recent spike in heart attack-related deaths in Hassan district. Her comments came in response to a social media post by the Chief Minister, in which he appeared to raise questions about the safety of the vaccines. Biotechnology pioneer Kiran Mazumdar-Shaw(PTI File Photo) In his post, Siddaramaiah revealed that over 20 individuals in Hassan district had died of heart attacks in the past month alone. While assuring the public that the government was treating the situation with utmost seriousness, he also raised the possibility that COVID-19 vaccinations might have contributed to these fatalities. READ | Four heart attack deaths in a day spark alarm in Hassan: Karnataka CM Siddaramaiah orders expert probe 'Orders were given to this same committee back in February to conduct a thorough study on the reasons behind sudden deaths among young people in the state, and whether the COVID vaccines could have any adverse effects,' Siddaramaiah wrote. 'It cannot be denied that the hasty approval and distribution of the Covid vaccine to the public could also be a reason for these deaths, as several studies worldwide have recently indicated that COVID vaccines could be a cause for the increasing number of heart attacks,' he added. READ | Karnataka orders probe as heart attacks rise in Hassan, 18 within a month Reacting to these remarks, Kiran Mazumdar-Shaw issued a pointed rebuttal. 'COVID-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation," she replied. 'These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their development, rather than engage in retrospective blame,' she further wrote. READ | Govt orders probe into Hassan cardiac deaths, vaccine link under lens The expert committee's findings are expected within the next ten days.
Mint
9 hours ago
- Mint
Bigger fonts, clearer tags: How the drug regulator is looking to redesign hard-to-read medicine labels
New Delhi: Ever squinted at a medicine strip trying to find the expiry date, or popped a pill without knowing whether it's branded or generic? You're not alone. India's top drug regulator is stepping in to change that. The Drug Controller General of India (DCGI) is working on a nationwide overhaul of medicine packaging and labelling norms. The goal is to make expiry dates and batch numbers easier to read, reduce confusion between generic and branded drugs, and help patients, make better-informed choices, two government officials aware of the matter said. As part of the proposed changes, manufacturers may soon be required to use larger fonts, ditch shiny packaging that reflects light and obscures print, and print expiry dates in more than one place to prevent vital information from being torn off. There's also a plan to introduce a universal symbol to clearly distinguish generic medicines from branded ones. The regulator had received several complaints regarding the difficulty in differentiating between cheaper generic drugs and their branded counterparts, and consequently, the pricing comparison. "The drug regulator has received various complaints and demands from the consumers regarding the labelling of medicinal products such as tiny font size of the letters printed on the drug packaging, shiny labels, the expiry date of the medicines getting torn while taking out the medicine, and demand for universally recognised symbol on the generic medicines that will distinguish it from the branded medicines," said one of the officials cited above requesting anonymity. A sub-committee, set up by the DCGI, is reviewing the proposals and is expected to submit its report soon, the second official said. The committee is also examining ways to incorporate these changes under the Drugs and Cosmetics Rules, 1945, which governs the quality of drugs manufactured, imported, and sold in the country. Queries sent to the health ministry on Monday and DCGI spokesperson on Tuesday remained unanswered till press time. Also Read: India's drug regulator plans overhaul of Schedule H for prescription medicines Branded vs generic While both generic and branded medicines contain the same active ingredient and are expected to have the same therapeutic effect, their key differences lie in cost, brand recognition, and patent status. Branded medicines such as a well-known painkiller, often carry a higher price tag due to the research, development, and extensive marketing by the innovator company. Generic medicines, on the other hand, are typically much cheaper (often 80-85% less) because they are manufactured after the original drug's patent expires, eliminating the need for costly R&D and marketing. For instance, if 'PainRelief Pro' is a popular branded drug for headaches, its generic equivalent, say 'Paracetamol 500mg', will offer the same relief at a fraction of the cost. But customers often miss this. They ask for affordable, quality medicines but are often unaware of generic alternatives, said Rajiv Singhal, president and General Secretary of the All India Organization of Chemists and Druggists (AIOCD) representing 1.2 million members in the country. He called for expiry and batch details to be printed in clearer, larger fonts in multiple places to prevent accidental torn off. 'If this regulation comes into play, companies will have to mandatorily follow," he said, emphasizing the importance of regulatory enforcement. The development assumes significance given that India holds the distinction of being the world's largest supplier of generic drugs, accounting for approximately 20% of the global supply and manufacturing around 60,000 generic brands across 60 therapeutic categories. Mint had earlier reported that DCGI was considering Braille labelling on drug packaging to support the 4.95 million blind and 70 million visually impaired people in India. Global standards Globally, drug labels tend to be much simpler. Dr. Viranchi Shah, national spokesperson for the Indian Drugs Manufacturers Association (IDMA), said Indian medicine strips are detailed compared to their international counterparts. For example, international labels often only state the tablet's name, omitting details like coating information or the explicit phrase "to be sold on the prescription of registered medical practitioners." Instead, the "Rx" symbol is commonly used to indicate a prescription requirement, with its absence signifying an over-the-counter (OTC) drug. The extensive information and specific font size requirements on Indian labels are seen as cumbersome, leading to substantial inventory costs and a significant financial burden on companies for redesigning packaging, Shah said. He said that the industry is open to changes for the greater good and informed that IDMA had previously submitted its representation to the DCGI years ago, suggesting simplified labelling. He said that a key hurdle to such changes is the significant inventory held by pharmaceutical companies. Changes to labelling would require a phased approach to avoid disruption. 'Any future changes, whenever and however implemented, should consider suggestions from both patients and the industry, and be introduced in a phased manner to minimize disruption." This step will empower patients and enhance transparency in the Indian pharmaceutical market, said Nikkhil K. Masurkar, CEO, Entod Pharmaceuticals. The current lack of visual cues on packaging, he said, often leaves patients unaware of generic alternatives. The government's Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) may also benefit from the labelling overhaul. PMBJP operates over 17,000 Janaushadhi Kendras across India to offer quality generic medicines at affordable rates. Also Read: Centre orders thorough safety review of painkiller Nimesulide for adults India's pharmaceutical market, meanwhile, continues to expand. According to Pharmarack, the Indian Pharmaceutical Market (IPM) reached ₹19,720 crore in sales for May 2025, showing a 7.2% YoY growth. On a moving annual total (MAT) basis, the industry posted ₹2.29 trillion, reflecting an 8.1% annual growth and 9.8% CAGR. While pharma companies may face some logistical costs in updating their packaging, the industry believes these are manageable and worth the impact on patient safety, affordability, and transparency.
